Unlocking the Future of Hepatocellular Carcinoma Early Diagnosis: The Promise of Extracellular Vesicle Biomarkers (IMAGE)
Caption
EVs have evolved from experimental biomarkers into a clinically actionable platform for HCC early detection, risk stratification, and targeted therapy. With the adoption of standardized isolation and characterization protocols—as defined by MISEV2023—and rigorous large-scale multicenter validation, EV-based liquid biopsy is poised to become an integral component of clinical guidelines for HCC management, transforming how this disease is detected and treated.
Credit
Yongcan Guo
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC